Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKDB-501A in Moderate-to-severe Glabellar Lines
NCT05292638Phase 1Completed
- Sponsor
- CKD BiO
- Start
- Feb 2022
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Microbial Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CKDB-501 in glabellar lines (2 arms), sponsored by CKD BiO. Primary endpoint: Incidence of Adverse Events. Started Feb 2022; status: completed.
02
Drugs
CKDB-501
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05292638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292638.